Drug intelligence / Profile preview

Frida Tablet

Development stage: Unknown
Lead developer: Serum Institute of India
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

Frida Tablet is a pharmaceutical product comprising a combination of Vitamin B9 (Folic Acid) and Iron. It is indicated for the treatment and prevention of iron deficiency anemia, as well as for addressing nutritional deficiencies, particularly during pregnancy and breastfeeding. Iron is an essential mineral vital for the formation of hemoglobin, which is responsible for oxygen transport in the body. Folic Acid, a B vitamin, plays a crucial role as a cofactor in DNA and amino acid synthesis, supporting cell division and the development of blood cells.

Brand names: Frida TabletFrida Injection

Beyond the preview

Go deeper on Frida Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frida Tablet.

Explore the full profile